Recent research into retatrutide, a dual activator for GLP-1 and GIP receptors, are demonstrating significant results in addressing obesity and type 2 diabetes. Initial information suggest a novel mechanism https://shopretatrutidepeptide.com/2026/03/12/what-is-retatrutide-peptide/